The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Open accessAbstract
Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Still, often phenotypes such as drug response observed in vitro have been unable to mirror in vivo models, likely due to factors missing in the tumor microenvironment that are absent from homogeneous cell lines cultures such as stromal and immune cells (Beaufort et al., 2014).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Beaufort et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 1×
“Sequence analysis and variant verification was performed as described previously [26,27].”
MethodThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“analysed genomic data for 47 ovarian cancer cell lines from the CCLE collection [13] for genetic similarity to highgrade serous ovarian carcinomas from the TCGA data [4,57].”
BackgroundIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
The Massachusetts Institute of Technology
Endowed, S. C. F. (1999) · Anthropology News · doi:10.1111/an.1999.40.2.6 · Cited by 3,132
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“Worldwide, there are about 100 ovarian cancer cell lines generated as described in literature [12–17] and about 70 of these are available at ATCC, ECACC, RIKEN, DSMZ, JCRB or Cancer Research Technology.”
BackgroundOne Hundred and Twenty-Seven Cultured Human Tumor Cell Lines Producing Tumors in Nude Mice23
Fogh, J., Fogh, J. M., & Orfeo, T. (1977) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/59.1.221 · Cited by 1,599
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484 · cited 1×
“The remaining histiotypes are mucinous, endometrioid and clear cell [3].”
BackgroundNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458 · cited 7×
“We used the expression data for 267 malignant ovarian carcinomas (GSE9891) [11] to determine the clinical significance of the morphological subtypes seen in our cell lines.”
BackgroundMethodInfluential
Flagged first, then by citations
Cited by
Sorted by citations
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,395
The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation
Liu, T., Wei, Q., Jin, J., Luo, Q., Liu, Y., Yu, Y., Cheng, C., Li, L., Pi, J., Si, Y., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa048 · Cited by 751
“Albeit A2780 and SKOV3 are most frequently used for ovarian cancer studies, particularly for high-grade serous ovarian cancer, they are probably originated from endometrioid or clear cell ovarian cancer (39).”
BackgroundHigh-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M. A., Fu, L., Goyeneche, A. A., Gao, Z., & Telleria, C. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 685
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
Medico, E., Russo, M., Picco, G., Cancelliere, C., Valtorta, E., Corti, G., Buscarino, M., Isella, C., Lamba, S., Martinoglio, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8002 · Cited by 302
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Main, H. G., Xie, J., Lantvit, D. D., Cárdenas, H., Fang, F., Liu, Y., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.040 · Cited by 214
Coscia, F., Watters, K. M., Curtis, M., Eckert, M. A., Chiang, C. Y., Tyanova, S., MONTAG, A. G., Lastra, R. R., Lengyel, E. R., & Mann, M. (2016) · Nature Communications · doi:10.1038/ncomms12645 · Cited by 210
“This group also contained the TOV112D and A2780 cell line pairs, previously described as endometrioid in origin 9,24,25 .”
Molecular mechanisms of drug resistance in ovarian cancer
Norouzi‐Barough, L., Sarookhani, M. R., Sharifi, M., Moghbelinejad, S., Jangjoo, S., & Salehi, R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26289 · Cited by 203
“Among the gynecological cancers, ovarian carcinoma is the most lethal malignancy and the sixth leading cause of cancer mortality among women worldwide (Beaufort et al., 2014; Sankaranarayanan & Ferlay, 2006).”
BackgroundACSL4 and polyunsaturated lipids support metastatic extravasation and colonization
Wang, Y., Hu, M., Cao, J., Wang, F., Han, J. R., Wu, T. W., Li, L., Yu, J., Fan, Y., Xie, G., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.047 · Cited by 197
TRIP13 regulates DNA repair pathway choice through REV7 conformational change
Clairmont, C. S., Sarangi, P., Ponnienselvan, K., Galli, L. D., Csete, I., Moreau, L. A., Adelmant, G., Chowdhury, D., Marto, J. A., & D’Andrea, A. D. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0442-y · Cited by 161
Au‐Yeung, G., Lang, F., Azar, W. J., Mitchell, T. J., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C. M., Pearson, R. B., Mileshkin, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 147
Ovarian cancer stem cells: still an elusive entity?
Lupia, M., & Cavallaro, U. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0638-3 · Cited by 149
Raghavan, S. A., Ward, M. R., Rowley, K. R., Wold, R. M., Takayama, S., Buckanovich, R. J., & Mehta, G. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.014 · Cited by 140
“demonstrated that the OVCAR3 cell line falls under the category of high-grade serous histotype, while the A2780 cell line was more representative of an endometrioid histotype [18].”
BackgroundLow-grade serous ovarian cancer: State of the science
Slomovitz, B. M., Gourley, C., Carey, M. S., Malpica, A. L., Shih, I., Huntsman, D. D., Fader, A. N., Grisham, R. N., Schlumbrecht, M. P., Sun, C. C., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.033 · Cited by 133
Barnes, B. M., Nelson, L., Tighe, A., Burghel, G. J., Lin, I., Desai, S. N., McGrail, J. C., Morgan, R. D., & Taylor, S. S. (2021) · Genome Medicine · doi:10.1186/s13073-021-00952-5 · Cited by 140
Natanzon, Y., Goode, E. L., & Cunningham, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.003 · Cited by 138
C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation
Liu, D., Zhang, X., Li, M., Cao, C., Wan, D., Xi, B., Tan, J., Wang, J., Yang, Z., Feng, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03590-5 · Cited by 127
Characterization of Ovarian Cancer Cell Lines as In Vivo Models for Preclinical Studies
Hernandez, L., Kim, M. K., Lyle, L. T., Bunch, K. P., House, C. D., Ning, F., Noonan, A. M., & Annunziata, C. M. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.028 · Cited by 121
“Recent studies have reported comprehensive data gathered for the most commonly available ovarian cancer cell lines (8, 9).”
Pape, V. F. S., Tóth, S., Füredi, A., Szebényi, K., Lovrics, A., Szabó, P. T., Wiese, M., & Szakács, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.078 · Cited by 114
Sun, X., Wang, S., Gai, J., Guan, J., Li, J., Li, Y., Zhao, J., Zhao, C., Fu, L., & Li, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00754 · Cited by 112
Hallas-Potts, A., Dawson, J. C., & Herrington, C. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41941-4 · Cited by 110
Zhang, X., Liu, D., Li, M., Cao, C., Wan, D., Xi, B., Li, W., Tan, J., Wang, J., Wu, Z., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0400-8 · Cited by 96
“inhibitors on a larger ovarian cancer cell line panel in vitro, we chose OV90 and CaOV3, which could represent high-grade serous ovarian cancer for CCK8 and colony formation assay [33].”
Altered glutamine metabolism in platinum resistant ovarian cancer
Hudson, C. D., Savadelis, A., Nagaraj, A. B., Joseph, P. L., Avril, S., DiFeo, A. V., & Avril, N. E. (2016) · Oncotarget · doi:10.18632/oncotarget.9317 · Cited by 95
“2) and endometrioid (A2780; [47, 48]) which together account for more than 90% of human ovarian cancer cases, thereby making our results highly clinically relevant.”
ResultKhalifa, A. M., Elsheikh, M. A., Khalifa, A., & Elnaggar, Y. S. R. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.034 · Cited by 95
Chung, V. Y., Tan, T. Z., Ye, J., Huang, R., Lai, H., Kappei, D., Wollmann, H., Guccione, E., & Huang, R. Y. (2019) · Communications Biology · doi:10.1038/s42003-019-0506-3 · Cited by 91
Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma
Coffman, L. G., Pearson, A. T., Frisbie, L. G., Freeman, Z. T., Christie, E. L., Bowtell, D. D. L., & Buckanovich, R. J. (2018) · Stem Cells · doi:10.1002/stem.2932 · Cited by 83
Current Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 92
Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells
Robinson, M., Gilbert, S. F., Waters, J. A., Lujano-Olazaba, O., Lara, J., Alexander, L. J., Green, S. E., Burkeen, G., Patrus, O., Sarwar, Z., et al. (2021) · Cancers · doi:10.3390/cancers13020262 · Cited by 84
“SOX2 reached significance across all the confirmed HGSOC lines, while OCT4 and NANOG expression was variable.”
ResultInfluentialYAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells
Hua, G., Lv, X., He, C., Remmenga, S. W., Rodabough, K. J., Dong, J., Yang, L., Lele, S. M., Yang, P., Zhou, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.288 · Cited by 83
“OVSAHO, a verified high grade ovarian serous carcinoma cell lines 43, 75 , have been used to replace the FT194-YAP S127A cells to confirm the role of verteporfin and BGJ398 on the growth of ovarian HGSC tumor in vitro using the same experimental design.”
Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 84
“Therefore, a shift in in vitro ovarian cancer research is warranted, restricting in vitro experiments to well-defined cell lines that have been characterized extensively (Anglesio et al., 2013; Beaufort et al., 2014).”
BackgroundHaley, J., Tomar, S., Pulliam, N., Xiong, S., Perkins, S. M., Karpf, A. R., Mitra, S., Nephew, K. P., & Mitra, A. K. (2016) · Oncotarget · doi:10.18632/oncotarget.9053 · Cited by 80
“” A number of the cell lines listed as “likely high-grade serous” in this study have had this status confirmed in other studies using a variety of metrics [5, 7, 9].”
BackgroundResultInfluentialvan Jaarsveld, M. T. M., van Kuijk, P. F., Boersma, A. W. M., Helleman, J., van IJcken, W. F. J., Mathijssen, R. H. J., Pothof, J., Berns, E. M. J. J., Verweij, J., & Wiemer, E. A. C. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0464-4 · Cited by 83
“Characteristics of the ovarian cancer cells were published in [50] and the authenticity of cell lines was verified by STR analysis.”
Harrington, B. S., He, Y., Davies, C. M., Wallace, S. J., Adams, M. N., Beaven, E. A., Roche, D., Kennedy, C. J., Chetty, N., Crandon, A. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.471 · Cited by 73
“…cancer, and although the immuno-phenotype of SKOV3 cells most closely resembles the profile seen in HGSC patients (Anglesio et al, 2013), it has recently been proposed that this line is poorly suited as a model for this malignancy (Anglesio et al, 2013; Domcke et al, 2013; Beaufort et al, 2014).”
BackgroundPark, G. B., & Kim, D. (2019) · Neoplasia · doi:10.1016/j.neo.2018.12.005 · Cited by 72
Elsnerová, K., Mohelníková-Duchoňová, B., Cerovská, E., Ehrlichová, M., Gut, I., Rob, L., Škapa, P., Hruda, M., Bartáková, A., Bouda, J., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4599 · Cited by 71
Huddle, B. C., Grimley, E. C., Buchman, C. D., Chtcherbinine, M., Debnath, B., Mehta, P., Yang, K., Morgan, C. A., Li, S., Felton, J. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00930 · Cited by 71
Anti-cancer effects of Kaempferia parviflora on ovarian cancer SKOV3 cells
Paramee, S., Sookkhee, S., Sakonwasun, C., Takuathung, M. N., Mungkornasawakul, P., Nimlamool, W., & Potikanond, S. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2241-6 · Cited by 68
“Since SKOV3 cells are known to be a high grade serous adenocarcinoma which has been reported to have high metastatic rate [16, 18].”
BackgroundYee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment
Xu, Y. (2018) · Cancers · doi:10.3390/cancers10070227 · Cited by 66
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
Betella, I., Turbitt, W. J., Szul, T., Wu, B., Martínez, A., Katre, A. K., Wall, J., Norian, L. A., Birrer, M. J., & Arend, R. C. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.010 · Cited by 65
Targeting the tumour microenvironment in platinum-resistant ovarian cancer
Cummings, M., Freer, C., & Orsi, N. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.007 · Cited by 65
Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer
Singh, M. S., Ramishetti, S., Landesman‐Milo, D., Goldsmith, M., Chatterjee, S., Palakuri, R., & Peer, D. (2021) · Small · doi:10.1002/smll.202100287 · Cited by 67
NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells
Zhou, Y., Zhu, Y., Fan, X., Zhang, C., Wang, Y., Zhang, L., Zhang, H., Wen, T., Zhang, K., Huo, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16145 · Cited by 64
“Beaufort and colleagues characterized a series of ovarian cancer cell lines into a spindle subtype and an epithelial subtype, based on hierarchical clustering using differentially expressed genes [18].”
BackgroundShang, S., Yang, J., Jazaeri, A. A., Duval, A. J., Tufan, T., Fischer, N. L., Benamar, M., Guessous, F., Lee, I.-Y., Campbell, R. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0215 · Cited by 67
“However, recent molecular profiling efforts suggested that the origin of some of these cell lines such as SKOV3 is likely non-serous epithelial ovarian cancer (25, 26).”
BackgroundDNA methylation changes in epithelial ovarian cancer histotypes
Earp, M. A., & Cunningham, J. M. (2015) · Genomics · doi:10.1016/j.ygeno.2015.09.001 · Cited by 58
Lee, J.-G., Ahn, J., Kim, T. J., Lee, J. H., & Choi, J. (2015) · Scientific Reports · doi:10.1038/srep12642 · Cited by 60
Gruosso, T., Garnier, C., Abélanet, S., Kieffer, Y., Lemesre, V., Bellanger, D., Bièche, I., Marangoni, E., Sastre‐Garau, X., Mieulet, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9583 · Cited by 70
Kashani, B., Zandi, Z., Bashash, D., Zaghal, A., Momeny, M., Poursani, E. M., Pourbagheri‐Sigaroodi, A., Mousavi, S. A., & Ghaffari, S. H. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03988-y · Cited by 57
GALNT14 Regulates Ferroptosis and Apoptosis of Ovarian Cancer Through the EGFR/mTOR Pathway
Li, H.-W., Liu, M., Jiang, X., Song, T., Feng, S., Wu, J., Deng, P., & Wang, X. (2021) · Future Oncology · doi:10.2217/fon-2021-0883 · Cited by 57
Nikas, I. P., Themistocleous, S., Paschou, S. Α., Tsamis, K. I., & Ryu, H. S. (2019) · Cells · doi:10.3390/cells9010019 · Cited by 54
“used the A2780 ovarian cancer cell line for their experiments [71], which was later found not to represent the most common histology type of ovarian cancer, the high-grade serous carcinoma [89,90].”
MethodMullen, M. M., Lomonosova, E., Toboni, M. D., Oplt, A., Cybulla, E., Blachut, B., Zhao, P., Noia, H. M., Wilke, D., Rankin, E. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0302 · Cited by 56
Bandolik, J. J., Hamacher, A., Schrenk, C., Weishaupt, R., & Kassack, M. U. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123052 · Cited by 55
“In addition to the four HGSOC cell lines, A2780 was included as a comparison model for ovarian endometrioid adenocarcinoma (type I) [28,29]—a less aggressive type of ovarian cancer.”
The Endometriotic Tumor Microenvironment in Ovarian Cancer
Wendel, J. R. H., Wang, X., & Hawkins, S. M. (2018) · Cancers · doi:10.3390/cancers10080261 · Cited by 51
“COV362 Endometrioid (pleural effusion) Serous TP53, BRCA1, RB1 *, EGFR, APC MYC [178,180,182,196]”
BackgroundBradbury, A., O'Donnell, R. L., Drew, Y., Curtin, N. J., & Saha, S. S. (2020) · Cancers · doi:10.3390/cancers12071939 · Cited by 52
“However, more recent studies such as Beaufort et al., 2014 [10] and the GDSC database (https: //www.cancerrxgene. rg/) highlight conflicting results.”
BackgroundResultInfluentialMei, J., Tian, H., Huang, H.-S., Hsu, C., Liou, Y., Wu, N., Zhang, W., & Chu, T. (2021) · Cell Proliferation · doi:10.1111/cpr.13029 · Cited by 50
Brodeur, M. N., Simeone, K., Leclerc-Deslauniers, K., Fleury, H., Carmona, E., Provencher, D. M., & Mes‐Masson, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-97434-w · Cited by 50
Slator, C., Barron, N., Howe, O. L., & Kellett, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00513 · Cited by 50
Kumar, N., Afjei, R., Massoud, T. F., & Paulmurugan, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-34696-x · Cited by 49
Bahar, E., Kim, J., Kim, H.-S., & Yoon, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207613 · Cited by 49
“To generate CisR OC cell lines, we selected two OC cell lines including the high-grade serous epithelial OC model cell line, OV-90, and the mixed epithelial OC cell line, SKOV-3 [41,42].”
MethodEffect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells
Schüler‐Toprak, S., Moehle, C., Skrzypczak, M., Ortmann, O., & Treeck, O. (2017) · BMC Cancer · doi:10.1186/s12885-017-3246-0 · Cited by 48
“OVCAR-3 cells were attained from ascites of a patient with highgrade serous ovarian cancer (G3) and exhibit a mutation of p53 [43].”
Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers
Price, C. O., Gill, S., Ho, Z. V., Davidson, S. M., Merkel, E., McFarland, J. M., Leung, L., Tang, A., Kost‐Alimova, M., Tsherniak, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2674 · Cited by 47
“To determine whether EGLN1 dependency was enriched in a specific subtype we grouped the ovarian cancer cell lines by historical pathological, molecular and histological subtypes [Supplementary Table 5, adapted from (31, 34, 36)].”
BackgroundMethodSox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells
Dorsett, K. A., Jones, R. B., Ankenbauer, K. E., Hjelmeland, A. B., & Bellis, S. L. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0574-5 · Cited by 47
Fan, Q., Cai, Q., & Xu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4280 · Cited by 46
“Recently, the most commonly used EOC cell lines, including A2780 and SKOV3, have been considered as non-HGSC cell lines [14, 38] based on genetic and functional characterizations.”
BackgroundGlucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT
Kanska, J. E., Aspuria, P.-J. P., Taylor‐Harding, B., Spurka, L., Funari, V. A., Oršulić, S., Karlan, B. Y., & Wiedemeyer, W. R. (2017) · Oncotarget · doi:10.18632/oncotarget.15429 · Cited by 47
“Similarly, we used CRISPR/Cas9 to deplete NNMT in SKOV3 ovarian cancer cells (endometrioid/clear cell subtype [40]), a cell line previously shown to have high NNMT activity [41].”
MethodCharacteristics of in Vivo Model Systems for Ovarian Cancer Studies
Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019) · Diagnostics · doi:10.3390/diagnostics9030120 · Cited by 46
“Only OVCAR3 cells, which are described as derived from poorly differentiated papillary adenocarcinoma [51], give such tumors in nude mice [52].”
BackgroundInfluentialHuman-Derived Model Systems in Gynecological Cancer Research
Lõhmussaar, K., Boretto, M., & Clevers, H. C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.07.007 · Cited by 47
Convergence of Wnt and Notch signaling controls ovarian cancer cell survival
Bocchicchio, S., Tesone, M., & Irusta, G. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28775 · Cited by 45
“…β‐catenin and Notch crosstalk could have therapeutic implications, at least, in serous/mucinous and endometroid/clear cells histological subtypes (Beaufort et al., 2014; Domcke, Sinha, Levine, Sander, & Schultz, 2013) C 1 10 20 0.00 0.25 0.50 0.75 1.00 1.25 Concentration of ICG-001 (μM)R el at…”
ResultInfluentialWu, N., Zhang, X., Fang, C., Zhu, M., Wang, Z., Jian, L., Tan, W., Wang, Y., Li, H., Xu, X., et al. (2024) · Research · doi:10.34133/research.0371 · Cited by 44
“Molecular characterization of A2780 cells also showed a non-HGSC profile with ARID1A , BRAF , PIK3CA , and PTEN mutations, microsatellite instability, and wild-type TP53 [51–53].”
BackgroundNanoparticle delivery systems to combat drug resistance in ovarian cancer
Miller, E., Samec, T., & Alexander-Bryant, A. A. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102309 · Cited by 47
Llauradó, M., DiMattia, G. E., Dawson, A., Bamford, S., Anderson, S. A., Hennessy, B. T., Anglesio, M. S., Shepherd, T. G., Salamanca, C. M., Hoenisch, J., et al. (2016) · PubMed Central · Cited by 42
Sonego, M., Pellizzari, I., Dall’Acqua, A., Pivetta, E., Lorenzon, I., Benevol, S., Bomben, R., Spessotto, P., Sorio, R., Gattei, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07005-1 · Cited by 43
Obermayr, E., Maritschnegg, E., Agreiter, C., Pecha, N., Speiser, P., Helmy-Bader, S., Danzinger, S., Krainer, M., Singer, C., & Zeillinger, R. (2017) · Oncotarget · doi:10.18632/oncotarget.22549 · Cited by 43
“We used two quite different cell lines for the spiking experiments, in terms of EpCAM protein expression, morphology, mutational status, doubling time, et cetera [25].”
MethodKallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer
Loessner, D., Goettig, P., Preis, S., Felber, J., Bronger, H., Clements, J. A., Dorn, J., & Magdolen, V. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1512587 · Cited by 43
“Beaufort and colleagues reported that OVCAR-3 have a high grade serous histology and a putative endometrioid/clear cell and clear cell histology for SKOV-3 and ES-2 cells respectively [46].”
BackgroundSun, X., Li, J., Li, Y., Wang, S., & Li, Q. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3145182 · Cited by 42
“In the control group, A2780 was round, SKOV-3 was epithelial-like, and CAOV-3 was spindle-shaped, in line with previous descriptions of these three OC cell lines [18].”
ResultCELLector: Genomics-Guided Selection of Cancer In Vitro Models
Najgebauer, H., Yang, M., Francies, H. E., Pacini, C., Stronach, E. A., Garnett, M. J., Sáez-Rodríguez, J., & Iorio, F. (2020) · Cell Systems · doi:10.1016/j.cels.2020.04.007 · Cited by 43
Brown, Y., Hua, S., & Tanwar, P. S. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.02.004 · Cited by 47
Hou, Z., Gattoc, L., O’Connor, C. E., Yang, S., Wallace-Povirk, A., George, C., Orr, S., Polin, L., White, K., Kushner, J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0444 · Cited by 42
“The subtypes of the EOC cell lines are as follows: IGROV1, mixed; TOV112D, endometrioid; SKOV3, serous; and A2780, nonspecified (29).”
BackgroundWithaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling
Straughn, A. R., & Kakar, S. S. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0586-1 · Cited by 42
“A limitation of the study was the cell line of choice used, as recent works have demonstrated that the A2780 cell line is more genetically similar to the relatively rarer endometroid ovarian cancers [50, 51] than high-grade serous ovarian cancer, which accounts for 70% of ovarian carcinomas [52].”
Ciucci, A., Buttarelli, M., Fagotti, A., Scambia, G., & Gallo, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04395-y · Cited by 44
“Beaufort and colleagues [10], through a comprehensive profiling of 39 commercially available cell lines, assigned half of them (20) as non-serous type, 14 as high-grade serous, and five as serous-type/low-grade serous.”
BackgroundGenomic characterization of five commonly used endometrial cancer cell lines
Devor, E. J., Bosquet, J. G., Thiel, K. W., & Leslie, K. K. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5139 · Cited by 41
“Since their original establishment, Ishikawa cells have been used as a model for type I endometrial cancer (11) in labs around the world and have appeared in >500 publications based on a PubMed (pubmed.”
BackgroundNorepinephrine-Induced DNA Damage in Ovarian Cancer Cells
Lamboy-Caraballo, R., Ortíz, C., Acevedo‐Santiago, A., Matta, J. L., Monteiro, Á. N. A., & Armaiz-Peña, G. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062250 · Cited by 41
“Thus, the cytotoxic effect of cisplatin may vary between cell type due to their different genomic background [35] and their ability to respond to cisplatin-induced DNA adducts.”
BackgroundMa, Q., Yang, F., Mackintosh, C., Jayani, R. S., Oh, S., Jin, C., Nair, S. J., Merkurjev, D., Ma, W., Allen, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2020.107532 · Cited by 37
Salvati, A., Gigantino, V., Nassa, G., Giurato, G., Alexandrova, E., Rizzo, F. M., Tarallo, R., & Weisz, A. (2019) · Cancers · doi:10.3390/cancers11111720 · Cited by 38
“All cell lines were isolated from peritoneal ascites of serous ovarian adenocarcinomas and carry TP53 mutations [43].”
BackgroundThe PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
Xiao, Y., Yu, Y., Jiang, P., Li, Y., Wang, C., & Zhang, R. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00514-8 · Cited by 39
“Additionally, several widely used epithelial ovarian cancer cells of unclear subtype (A2780, A2780CP, SKOV3, SKOV3TR and SKOV3IP) or with a mixed subtypes (IGROV-1 and HO8910PM), were included [37, 38].”
BackgroundKLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
Donato, M. D., Babini, G., Mozzetti, S., Buttarelli, M., Ciucci, A., Arduini, G., Rosa, M. C. D., Scambia, G., & Gallo, D. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01775-9 · Cited by 39
Coulson‐Gilmer, C., Morgan, R. D., Nelson, L., Barnes, B. M., Tighe, A., Wardenaar, R., Spierings, D. C. J., Schlecht, H., Burghel, G. J., Foijer, F., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02124-0 · Cited by 38
“Indeed, two of the PARGi-resistant cell lines, COV362 and OVSAHO, have reported BRCA defects [45, 66, 67] and are PARPi-sensitive.”
BackgroundMouse models of epithelial ovarian cancer for preclinical studies
Karakashev, S. V., & Zhang, R. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.382 · Cited by 42
“… lines used in earlier EOC xenograft mouse model studies were SKOV3 and A2870, which were later shown to have originated from ovarian surface epithelium and endometrium tissues, and therefore were not representative of HGSOC (Beaufort et al., 2014; Domcke et al., 2013).”
BackgroundTomar, T., de Jong, S., Alkema, N. G., Hoekman, R. L., Meersma, G. J., Klip, H. G., van der Zee, A. G., & Wisman, G. B. A. (2016) · Genome Medicine · doi:10.1186/s13073-016-0361-5 · Cited by 39
“Recent genomic analyses have shown that most commonly used HGSOC cell lines, like SKOV3 and A2780, are less representative models of HGSOC [8, 9].”
Rochford, G., Molphy, Z. E., Kavanagh, K. A., McCann, M., Devereux, M. M., Kellett, A., & Howe, O. L. (2019) · Metallomics · doi:10.1039/c9mt00187e · Cited by 38
Zhao, Y., He, M., Cui, L., Gao, M., Zhang, M., Yue, F., Shi, T., Yang, X., Pan, Y., Zheng, X., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0825-7 · Cited by 38
“The putative histological subtype was endometrioid or clear cell.(38) Our results first indicated that all the three cell lines showed similar response to the first- or secondline chemotherapy treatments: the increase in CSC-like characteristics and migration.”
ResultClinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
Buttarelli, M., Donato, M. D., Raspaglio, G., Babini, G., Ciucci, A., Martinelli, E., Baccaro, P., Pasciuto, T., Fagotti, A., Scambia, G., et al. (2020) · Cancers · doi:10.3390/cancers12040966 · Cited by 38
Färkkilä, A., Rodríguez, A., Oikkonen, J., Gulhan, D., Nguyen, H. Q., Domínguez, J., Ramos, S., Mills, C. E., Pérez‐Villatoro, F., Lazaro, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2912 · Cited by 39
“Previous studies on PARPi resistance have been performed in commercially available BRCA1-deficient cell lines derived from drug-resistant tumors (20, 21) and have focused on single mechanism of resistance (13, 14).”
BackgroundNorouzi‐Barough, L., Sarookhani, M. R., Salehi, R., Sharifi, M., & Moghbelinejad, S. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2017.25145.6230 · Cited by 38
Faddaoui, A., Bachvarova, M., Plante, M., Gregoire, J., Renaud, M., Sebastianelli, A., Gobeil, S., Morin, C., Macdonald, E. A., Vanderhyden, B. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7288 · Cited by 37
“SKOV3 represents a serous EOC cell line displaying mesenchymal (spindle-like) phenotype, including no evidence of cell-cell adhesion [24].”
Mutant p53 gain of function induces HER2 over-expression in cancer cells
Román-Rosales, A., Garcı́a-Villa, E., Herrera, L. A., Gariglio, P., & Díaz‐Chávez, J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4613-1 · Cited by 37
Three-Dimensional Biofabrication Models of Endometriosis and the Endometriotic Microenvironment
Wendel, J. R. H., Wang, X., Smith, L. J., & Hawkins, S. M. (2020) · Biomedicines · doi:10.3390/biomedicines8110525 · Cited by 35
“The HEYA8 cell line formed tight, dense spheroids [26] and has been well characterized molecularly as non-high-grade serous [73,74].”
BackgroundPARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers
Ali, R., Alabdullah, M., Alblihy, A., Miligy, I. M., Mesquita, K. A., Chan, S. Y. T., Moseley, P. M., Rakha, E. A., & Madhusudan, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.035 · Cited by 36
Ali, R., Alblihy, A., Miligy, I. M., Alabdullah, M. L., Alsaleem, M. A., Toss, M. S., Algethami, M., Abdel-Fatah, T. M. A., Moseley, P. M., Chan, S. Y. T., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01710-y · Cited by 36
Esposito, A., Ferraresi, A., Salwa, A., Vidoni, C., Dhanasekaran, D. N., & Isidoro, C. (2022) · Cancers · doi:10.3390/cancers14092142 · Cited by 37
Ovarian Cancer: Treatment and Resistance to Pharmacotherapy
Lukanović, D., Kobal, B., & Černe, K. (2022) · Reproductive Medicine · doi:10.3390/reprodmed3020011 · Cited by 35
“This way, they formed the basis for selecting the models of various histological and molecular ovarian cancer types [71].”
BackgroundThe novel ZIP4 regulation and its role in ovarian cancer
Fan, Q., Cai, Q., Li, P., Wang, W., Wang, J., Gerry, E., Wang, T., Shih, I., Nephew, K. P., & Xu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21435 · Cited by 35
“The majority of the data generated in Seo’s work used A2780 and SKOV3 cell lines, which are not HGSOC [45, 46].”
BackgroundInfluential
Metadata
- Authors
- Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., Koudijs, M. J., Brenton, J. D., Berns, E. M. J. J., & Helleman, J.
- Affiliations
- Erasmus MC Cancer Institute (NL)
- University of Cambridge (GB)
- University Medical Center Utrecht (NL)
- Corresponding author
- Berns, Els M. J. J.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-17
- Volume
- 9
- Issue
- 9
- Pages
- e103988
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4167545
- OpenAlex
- W2015030879
- Cited by
- 403
- References
- 89
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 30 · 2023: 48 · 2022: 38 · 2021: 54 · 2020: 52 · 2019: 41 · 2018: 27 · 2017: 28 · 2016: 25 · 2015: 21
- FWCI
- 29.95
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-03-23)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Cancer Research UK (15601)
- Universitair Medisch Centrum Utrecht
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- epithelial ovarian cancer, ovarian cancer cell lines, morphological subtypes, high-grade serous carcinoma, low-grade serous carcinoma, tumor heterogeneity, metastasis, prognosis, drug response, preclinical models
- MeSH terms
- Carcinoma, Ovarian Epithelial, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
